AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01132703
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the Treatment Arm.
Trial: NCT01119443
Drug: PPX ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPX ER 0.375mg - 1.5mg for 32 days totally
Trial: NCT01201551
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Week1, day1: 1 eyedrop/left eye Week1, day2: 2 eyedrops/left eye Week2, day1: 1 eyedrop/right eye Week2, day2: 2 eyedrops/right eye
Trial: NCT04157699
Drug: TDF tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDF tablet 300mg QD
Trial: NCT04157699
Drug: QL-007
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QL-007 tablet
Trial: NCT00439335
Drug: Placebo (IM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo will be 0.1 mL of saline administered by the IM route.
Trial: NCT00439335
Drug: Placebo (ID)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo will be 0.1 mL of saline administered by the ID route.
Trial: NCT01144143
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the placebo will be injected into the joint through a needle
Trial: NCT01144143
Drug: Standard of Care: Methylprednisolone acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone acetate will be injected into the joint through a needle
Trial: NCT00263003
Drug: Irbesartan/hydrochlorothiazide
RxNorm normalized name: irbesartan/hydrochlorothiazide 300 mg-25 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00512278
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00753948
Drug: N-Nitro L-arginine-methylester (L-NAME)
RxNorm normalized name: .alpha.N-(methoxycarbonyl)-L-arginine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A non-specific inhibitor of the nitric oxide synthase enzyme.
Trial: NCT02345616
Drug: Nitric oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02491281
Drug: LNA043
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ascending single dose on Day 1; 1 to 4 week(s) prior total knee replacement surgery
Trial: NCT02491281
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ascending single dose on Day 1; 1 to 4 week(s) prior total knee replacement surgery
Trial: NCT01452477
Drug: tanshinone placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo 1.0g / time, 3 times / day orally, continuous treatment for 12 weeks.
Trial: NCT00609752
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard treatment regimens based on body weight will be used (approximately 2 mg per kg), with a stepwise dose reduction over a 10-14 week period.
Trial: NCT02639247
Drug: SOF/VEL/VOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400/100/100 mg FDC tablet administered orally once daily with food
Trial: NCT02639247
Drug: SOF/VEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400/100 mg FDC tablet administered orally once daily without regard to food
Trial: NCT03045887
Drug: GSK2292767 50 μg
RxNorm normalized name: penicillin G 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2292767 50 μg blended with lactose and magnesium stearate per blister as powder for inhalation
Trial: NCT03045887
Drug: GSK2292767 500 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2292767 500 μg blended with lactose and magnesium stearate per blister as powder for inhalation
Trial: NCT03045887
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose as powder for inhalation
Trial: NCT02862977
Drug: ketoprofen and cyclobenzaprine association with caffeine
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patient will take 2 tablets (combination of ketoprofen and cyclobenzaprine and caffeine), oral, per day, each 12h
Trial: NCT02862977
Drug: Cyclobenzaprine with caffeine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient will take 2 tablets (combination of cyclobenzaprine and caffeine), oral, per day, each 12h
Trial: NCT03294395
Drug: Gentamicin Sulfate, Injectable
RxNorm normalized name: Gentamicin Sulfate, Injectable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose 5mg/kg (maximum 400mg) intramuscular injection
Trial: NCT01913847
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo TID for 12 weeks
Trial: NCT03368196
Drug: DS-8201a
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An antibody drug conjugate
Trial: NCT01118780
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by mouth, daily for 10 weeks
Trial: NCT00870480
Drug: Proscar® 5 mg Tablet, single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B: Active comparator Subjects received Merck Sharp and Dohme, U.S.A formulated products under fasting conditions
Trial: NCT02864264
Drug: Placebo matching BMS-986184
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00705874
Drug: CGC-11047 and 5-flurouracil / leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-Flurouracil / Leucovorin: Leucovorin 500 mg/m2 IV over 2 hours with 5 - FU 500 mg/m2 IV bolus starting 1 hour into leucovorin infusion weekly for 6 wks, repeated every 56 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
Trial: NCT02326727
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: General Anesthesia
Trial: NCT02719392
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Minocycline is an FDA-approved antibiotic commonly used to treat bacterial infections.
Trial: NCT04283006
Drug: CD20/CD22 dual Targeted CAR T-cells
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject receive CD20/CD22 dual Targeted CAR T-cells by intravenous infusion
Trial: NCT01406600
Drug: recombinant hCG (Ovidrel®)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant hCG (Ovidrel®)will be administrated for final oocyte maturation triggering in poor responders with different two doses (250mcg vs. 500mcg). Usually rhCG is administrated after 24\~48 hours from optimal ovarian stimulation status.
Trial: NCT00533429
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, daily
Trial: NCT03809273
Drug: Yangxinshi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yangxinshi pill 3 pills /tid
Trial: NCT02592421
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Comparator
Trial: NCT02553187
Drug: Kanglaite Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mL, slow IV drip, once daily for 14 consecutive days, subsequent courses repeated after a 7-day interval.~Subjects will be treated for 4 courses (12 weeks).
Trial: NCT03506620
Drug: Saline Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 cc of saline will be injected in the form of a QL block as a placebo.
Trial: NCT00509327
Drug: glucosemonohydricum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg of glucosemonohydricum twice daily from one day preoperative to day three postoperative
Trial: NCT00300378
Drug: desvenlafaxine 50 mg
RxNorm normalized name: desvenlafaxine 50 MG
DrugBank: Desvenlafaxine (DB06700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00300378
Drug: desvenlafaxine 100 mg
RxNorm normalized name: desvenlafaxine 100 MG
DrugBank: Desvenlafaxine (DB06700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02710188
Drug: HTL0009936 modified release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTL0009936 modified release
Trial: NCT02710188
Drug: HTL0009936 immediate release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTL0009936 immediate release
Trial: NCT00803361
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsules, oral, once a day for 15 weeks
Trial: NCT01694004
Drug: Benzocaine Infusion into Duodenum
RxNorm normalized name: Sus scrofa duodenum preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02020590
Drug: ALLOB® implantation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each patient will undergo a single administration of ALLOB® into the delayed-union site under anesthesia.
Trial: NCT03521791
Drug: PRO-155
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRO-155 (Zebesten ofteno®) Active agent: bromfenac 0.90 mg / mL, dropper bottle of low density polyethylene for multidose administration in the form of an ophthalmic solution of 5 mL (milliliters). Sanitary registry in Mexico: 108M2014~Sodium hyaluronate 0.4% \[Lagricel ofteno®\] 1 drop 3 times a day in the period of vigil in the conjunctival cul-de-sac
Trial: NCT01122979
Drug: Regular insulin
RxNorm normalized name: Regular insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: dose adjusted to the patient's glycemia
Trial: NCT01186250
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo taken daily for one year
Trial: NCT02273102
Drug: Tretinoin
RxNorm normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 45 mg/m2 of ATRA to be administered orally twice a day (12 hours apart), beginning on day 4 for up to 16 cycles of 21 days each.
Trial: NCT01655186
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01022970
Drug: QAX576 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01022970
Drug: QAX576
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03965182
Drug: PEG plus SPMC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one sachet of PEG and one sachet will be administered as the bowel prep regimen
Trial: NCT03965182
Drug: SPMC
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 sachets will be administered as the bowel prep regimen.
Trial: NCT02706925
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00600067
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo capsules, once daily, 28 weeks
Trial: NCT02132897
Drug: Auration CR Tablets 400 Single Dose-Tegretol CR 400 Single Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine CR Tablets 400 milligrams is given orally with 250 mL of water at room temperature.
Trial: NCT02564588
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily
Trial: NCT01224236
Drug: Iron Supplement
RxNorm normalized name: Iron supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg/day elemental iron as multivitamin with iron solution
Trial: NCT01842373
Drug: BLT
RxNorm normalized name: BLT-25
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00932074
Drug: KP-413 Ointment
RxNorm normalized name: Draxxin KP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study drug ointment to be applied topically to the selected treatment areas on the head/neck and torso/limbs twice a day for 4 weeks.
Trial: NCT00570713
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As per package insert.
Trial: NCT01600404
Drug: antimuscarinic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01781377
Drug: PLACEBO
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SALINE INFUSION
Trial: NCT01462929
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage form: Dry powder Route of administration: Oral inhalation by Genuair multidose dry powder inhaler. 1 puff of placebo in the morning (09:00 ± 1h) and 1 puff in the evening (21:00 ± 1h) AND Oral inhalation by HandiHaler single-dose dry powder inhaler. 1 puff of placebo in the morning (09:00 ± 1h).
Trial: NCT03240562
Drug: patient controlled analgesia
RxNorm normalized name: PATIENT CONTROLLED ANALGESIA VIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two groups have same intravenous patient controlled analgesia
Trial: NCT01583114
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: form:1 tablet contained 5 mg placebo; posology: 1 intake per day, initiated at a dose of 2.5 mg (1/2 tablet) per day during one week, then 5 mg (1 tablet) per day during two weeks, then 10 mg (2 tablets), or the maximal dose tolerated, until the end of the study (36 months).
Trial: NCT04481607
Drug: TQB3454
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB3454 tablets is a small molecule oral drug.
Trial: NCT02554799
Drug: MMV390048 formulation B
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMV390048 formulation B, tablet
Trial: NCT01820806
Drug: 100 mg dose of [14C] GLPG0634
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be dosed with a single oral 100 mg dose of \[14C\] GLPG0634 on one occasion
Trial: NCT00977483
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet once daily 4 years double-blind treatment period
Trial: NCT02250872
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg in 2 divided doses plus cisplatin
Trial: NCT00287950
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01365793
Drug: 0.45% saline replacement fluid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10cc/Kg bolus of 0.9% saline followed by 0.45% saline used as the replacement fluid
Trial: NCT01365793
Drug: 0.9% saline replacement fluid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10cc/Kg bolus of 0.9% saline followed by 0.9% saline used as the replacement fluid.
Trial: NCT01365793
Drug: 0.45% saline intravenous fluid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.45% saline fluid
Trial: NCT01365793
Drug: 0.9% saline Intravenous fluid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline fluid
Trial: NCT02808429
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received placebo matched to Atacicept once weekly as subcutaneous (SC) injection during this study up to a maximum of 72.1 weeks.
Trial: NCT00618007
Drug: PF-00734200 30 mg QD
RxNorm normalized name: CODEINE PO4 30MG/ML (PF) INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg QD
Trial: NCT00618007
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01436110
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation powder via Novel Dry Powder Inhaler and DISKUS?ACCUHALER
Trial: NCT01847092
Drug: AZD1722
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01847092
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for AZD1722
Trial: NCT01658553
Drug: GSK1120212
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1120212 - placebo match oral dose on day 1 with GSK1120212 3 mg oral dose on day 15. GSK1120212 2mg and 2 tablets of GSK1120212 -placebo matched 0.5 mg oral dose daily from day 2 to day 14. 24 hour holter monitoring will be performed on day 1 and day 15 to compare the subjects cardiac repolarization while on placebo and after having received GSK1120212 for 14 days
Trial: NCT01864265
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered according to the label of the biological
Trial: NCT01244035
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-8266 1.3 mg orally twice daily (BID, 1 mg in the morning and 0.3 mg 8 hours later) plus placebo to match Treatment B on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.
Trial: NCT01244035
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-8266 0.1 mg orally administered every 2 hours as frequent divided dosing (FDD, total dose of 0.9 mg) plus placebo to match Treatment A on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.
Trial: NCT02432937
Drug: Corever
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Corever
Trial: NCT00641108
Drug: ADAM SPECT plus Cognitive Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00641108
Drug: ADAM SPECT plus No Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04527055
Drug: Tetracycline Pill
RxNorm normalized name: tetracycline Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracycline (250 MG) 2 tab per oral four times per day for 14 days in the14-day bismuth-based quadruple therapy and for 10 days in the10-day bismuth-based quadruple therapy
Trial: NCT00886418
Drug: muscle relaxant
RxNorm normalized name: MUSCLE RELAXANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: muscle relaxant administration throughout anesthesia
Trial: NCT00886418
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no muscle relaxant throughout anesthesia (normal saline infused as a placebo)
Trial: NCT03067792
Drug: 5-fluorouracil, irinotecan and leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In FOLFIRI group, patients received irinotecan 180 mg/m2 and 5-fluorouracil 400mg/m2 intravenously bolus injection on days 1 and leucovorin 200mg/m2 for 2 hours and 5-fluorouracil 600mg/m2 for 22 hours intravenously infusion on day 2 of a 14-day cycle.
Trial: NCT03899584
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo arm will include a placebo of microcrystalline cellulose.
Trial: NCT04149483
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One with the intervention (Placebo, 20mg OD), 30 patients for this arm.
Trial: NCT01769833
Drug: Nucleosides
RxNorm normalized name: Nucleosides and nucleotides excl. reverse transcriptase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01623505
Drug: Transdermal Nicoderm patch combined with gum or inhaler
RxNorm normalized name: Nicoderm C-Q Transdermal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receiving this treatment will set a quit date within 2 weeks after baseline assessment and apply the patch on that day. This group will follow the same regimen as the standard patch treatment, but is not limited to a fixed dosing strategy. Participants will be advised on the titration of patch (increase or decrease in dosage) to ensure elimination of withdrawal symptoms (maximum dosage of 35mg/day, maximum treatment of up to 22 weeks). Participants will be provided with either gum or inhaler to manage cravings.~All participants will receive six 15-minute counselling sessions from a nurse-counsellor specializing in smoking cessation.~\*Off-label dosage approved by Health Canada via No Objection letter.
Trial: NCT01623505
Drug: Transdermal Nicoderm patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receiving this treatment group (standard treatment)will set a target quit date within the 2 weeks after baseline assessment and start to apply the patch on that day. This treatment will consist of a 10-week supply of nicotine patches. The initial dosage will be determined from the average number of cigarettes smoked each day as per the manufacturer's recommendation. Participants smoking ≥ 20 cigarettes per day will be prescribed 21 mg/24 hours for 6 weeks, 14 mg/24 hours for 2 weeks, and 7 mg/24 hours for 2 weeks. Participants smoking 11 - 20 cigarettes per day will be prescribed 14 mg/24 hours for 6 weeks, and 7 mg/24 hours for 4 weeks.~All participants will receive six 15-minute counselling sessions from a nurse-counsellor specializing in smoking cessation.
Trial: NCT00507585
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 300 mg/m\^2 IV over 10 Minutes, then 600 mg/m\^2 IV over 22 Hours repeated every 3 weeks (1 Cycle).
Trial: NCT00507585
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg/m\^2 IV Over 2 Hours repeated every 3 weeks (1 Cycle).
Trial: NCT01616277
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for PF-06252616, IV infusion, single dose
Trial: NCT01616277
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for PF-06252616, Subcutaneous injection, single dose
Trial: NCT01616277
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for PF-06252616, IV infusion, repeat dose
Trial: NCT00373048
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet, once weekly
Trial: NCT04590599
Drug: IBI310
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBI310 3 mg/kg,Q3W, for a total of 4 cycles
Trial: NCT04590599
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Q3W, for a total of 4 cycles
Trial: NCT01354522
Drug: Docetaxel, Doxorubicin, Cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: docetaxel 75 mg/m², iv, day 1 doxorubicin 50 mg/m² or epirubicin 75mg/m², iv, day 1 Cyclophosphamide 500 mg/m², iv, day 1 every 3 weeks for 6 cycles
Trial: NCT01354522
Drug: Docetaxel, Cyclophosphamide, Capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: docetaxel 75 mg/m², iv, day 1 Cyclophosphamide 500 mg/m², iv, day 1 capecitabine 950 mg/m2, twice a day, via oral intake, day 1 to day 14 every 3 weeks for 6 cycles